Clinical Trials Browser

Phase 1/2 × anlotinib × Gynecologic × Clear all

NCT04157491 2019-11-08

Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer

Phase 1/2 Unknown

Endometrial Neoplasms

NCT02558348 2019-06-19

AL3818

Phase 1/2 Terminated

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms